Artiva Biotherapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $232.14M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 8, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | – | $-0.87 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | $-0.83 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $0 | $-0.92 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 29, 2024 | After market close | – | – | – |
Press releases
Announcements Artiva Biotherapeutics filed with the SEC
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Artiva Announces Positive Initial Clinical Data with AlloNK ® Across Multiple
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements.
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K